邢诗伟,张志刚

肺癌是全球癌症相关死亡的首要原因，除吸烟等传统因素外，病毒感染的作用日益受到关注。人乳头瘤病毒（human papillomavirus，HPV）作为明确的致癌病毒，与宫颈癌、头颈癌等多种恶性肿瘤密切相关。近年来，大量研究探索了HPV与肺癌的关联，但因果性仍存在争议。研究的检测方法、样本量、地区分布等差异导致研究结果间出现明显分歧。本文基于近期文献，对HPV在肺癌诊疗中的研究现状进行梳理。

HPV；肺癌；mRNA；E6；E7

[1] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. [2] Akhtar N,Bansal JG.Risk factors of Lung Cancer in nonsmoker[J].Curr Probl Cancer,2017,41(5):328-339. [3] Osorio JC,Candia-Escobar F,Corvalán AH,et al.High-Risk Human Papillomavirus Infection in Lung Cancer:Mechanisms and Perspectives[J].Biology(Basel),2022,11(12):1691. [4] Syrjänen KJ.Condylomatous changes in neoplastic bronchial epithelium.Report of a case[J].Respiration,1979,38(5):299-304. [5] Chen Y,Xu Z,Zhang Z,et al.No genetic causal association between human papillomavirus and lung cancer risk:a bidirectional two- sample Mendelian randomization analysis[J].Trials,2024,25(1):582. [6] Sequeira T,Pinto R,Cardoso C,et al.HPV and Lung Cancer:A Systematic Review[J].Cancers(Basel),2024,16(19):3325. [7]Zou DJ,Zhao YB,Yang JH,et al.Expression and Significance of HPV16 E6/E7 mRNAs in the Bronchial Brush and TBNA Cells of Patients With Small Cell Lung Cancer[J].Technol Cancer Res Treat,2021,20:15330338211019505. [8] Yu Y,Liu X,Yang Y,et al.Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development[J].Oncol Lett,2015,10(1):392-398. [9] de Oliveira THA,do Amaral CM,de França São Marcos B,et al.Presence and activity of HPV in primary lung cancer[J].J Cancer Res Clin Oncol,2018,144(12):2367-2376. [10] Yanagawa N,Wang A,Kohler D,et al.Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients[J].Lung Cancer,2013,79(3):215-220. [11] Huang JY,Lin C,Tsai SC,et al.Human Papillomavirus Is Associated With Adenocarcinoma of Lung:A Population-Based Cohort Study[J].Front Med(Lausanne),2022,9:932196. [12] Bhaliya K,Anwer M,Wei MQ.Emerging Therapeutic Strategies for Lung Cancer:The Role of Immunotherapy and HPV-Targeted Cancer Vaccines[J].Vaccines(Basel),2025,13(9):957. [13] Zou DJ,Zhao YB,Yang JH,et al.Expression and Significance of HPV16 E6/E7 mRNAs in the Bronchial Brush and TBNA Cells of Patients With Small Cell Lung Cancer[J].Technol Cancer Res Treat,2021,20:15330338211019505. [14] Drokow EK,Effah CY,Agboyibor C,et al.Microbial infections as potential risk factors for lung cancer:Investigating the role of human papillomavirus and chlamydia pneumoniae[J].AIMS Public Health,2023,10(3):627-646. [15] Rojas L,Mayorga D,Ruiz-Patiño A,et al.Human papillomavirus infection and lung adenocarcinoma:special benefit is observed in patients treated with immune checkpoint inhibitors[J].ESMO Open,2022,7(4):100500. [16] Wang JL,Lee WJ,Fang CL,et al.Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer[J].Cancers(Basel),2022,14(21):5333. [17] Antonia SJ,Villegas A,Daniel D,et al.Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J].N Engl J Med,2017,377(20):1919-1929. [18] Liu C,Lu J,Tian H,et al.Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity[J].Mol Med Rep,2017,15(3):1063-1070. [19] Wang JL,Lee WJ,Fang CL,et al.Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer[J].Cancers(Basel),2022,14(21):5333. [20] Mo Y,Ma J,Zhang H,et al.Prophylactic and Therapeutic HPV Vaccines:Current Scenario and Perspectives[J].Front Cell Infect Microbiol,2022,12:909223. [21] Wang J,Wang Q,Ma L,et al.Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies[J].Mol Ther,2024,32(7):2340-2356. [22] Baden LR,El Sahly HM,Essink B,et al.Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine[J].N Engl J Med,2021, 384(5):403-416. [23] Jahanafrooz Z,Baradaran B,Mosafer J,et al.Comparison of DNA and mRNA vaccines against cancer[J].Drug Discov Today,2020, 25(3):552-560. [24] 曹学智,彭华,傅阳心.基于mRNA-LNP的肿瘤免疫疗法[J].中国肿瘤生物治疗杂志,2022,29(07):605-612. [25] Ott PA,Hu-Lieskovan S,Chmielowski B,et al.A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma,Non-small Cell Lung Cancer,or Bladder Cancer[J].Cell,2020,183(2):347-362.e24. [26] Wu DW,Jia SP,Xing SJ,et al.Personalized neoantigen cancer vaccines:current progression,challenges and a bright future[J].Clin Exp Med,2024,24(1):229.

点击下载PDF